Market News & Trends
Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating Investigational T Cell Vaccine for the Prevention of HIV
Vir Biotechnology, Inc. recently announced the first participant has been dosed in a Phase 1 trial evaluating the safety, reactogenicity, and immunogenicity of VIR-1388, an investigational novel T cell vaccine for….
LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, Plus GSK’s Immunotherapy in Clear-Cell Ovarian Cancer
The Phase 1b Clinical Trial Focuses on Assessing the Safety and Efficacy of the Two-Drug Combination in a Cancer Associated with Longer Survival to Immunotherapy When Genetically Deficient in PP2A….
ALSA Ventures Launches Novel Gene Therapy Portfolio Company Axovia Therapeutics
ALSA Ventures recently announced the acquisition of Axovia Therapeutics Inc and the launch of a new portfolio company Axovia Therapeutics Ltd. Axovia is developing the…
Rhythm Pharmaceuticals Receives Orphan Drug Designation for Setmelanotide for Treatment of Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals, Inc. recently announced the European Medicines Agency (EMA) has issued a positive opinion on the company’s orphan drug designation request for setmelanotide as…
BioSenic Publishes New Evidence of Beneficial Effects of Arsenic Trioxide Treatment Supporting Clinical Trial for Systemic Sclerosis
BioSenic recently announced publication of data providing additional key indications of its lead API (Active Pharmaceutical Ingredient) arsenic trioxide (ATO) to treat systemic sclerosis (SSc)…
Samsung Biologics Announces Expanded Strategic Agreement With Bristol Myers Squibb
Samsung Biologics recently announced a new agreement with Bristol Myers Squibb for large-scale manufacturing of a Bristol Myers Squibb commercial antibody cancer drug….
BioNTech & CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development & Support CEPI’s 100 Days Mission
BioNTech SE and the Coalition for Epidemic Preparedness Innovations (CEPI) recently announced a strategic partnership to advance mRNA-based vaccine candidates with the development of….
Orchard Therapeutics Announces Acceptance of BLA for OTL-200 in MLD; Receives Priority Review
Orchard Therapeutics recently announced the US FDA has accepted the filing of its Biologics License Application (BLA) for OTL-200 in metachromatic leukodystrophy (MLD) under Priority…
Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill Containing Ustekinumab Biosimilar, CT-P43)
Rani Therapeutics Holdings, Inc. recently announced the initiation of a Phase 1 clinical trial to evaluate the safety and tolerability of RT-111, an orally administered…
POINT Biopharma & Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands
POINT Biopharma Global Inc. and Athebio AG recently announced a collaboration and license agreement to develop and commercialize DARPin-targeted radioligands (Radio-DARPins). DARPins are an attractive…
New Collaboration With Stevanato Group to Elevate mRNA Production With Nfinity Platform
Quantoom Biosciences recently announced a new collaboration with Stevanato Group, a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life science industries, with the goal of….
First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod From Sanofi
First Wave to develop and repurpose Capeserod for gastrointestinal (GI) indications based on AI-empowered analyses, expanding the company’s GI-focused pipeline….
Anavex’s Phase 2b/3 Trial of Blarcamesine in Patients With Alzheimer’s Disease Shows Robust Clinical Efficacy & Slows Neurodegeneration
Anavex Life Sciences Corp. recently announced that a follow-on analysis of the landmark Phase 2b/3 study to treat early Alzheimer’s disease with the investigational drug…
Evoke Pharma Receives Notice of Allowance from USPTO for First & Only FDA-Approved Nasal Formulation of Metoclopramide Commercially Available in the US
Evoke Pharma, Inc. recently announced it has been granted a Notice of Allowance from the US Patent and Trademark Office (USPTO) for patent application No.…
Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis
Hepion Pharmaceuticals, Inc. recently announced positive results from a translational research study in which Hepion’s lead drug candidate, rencofilstat, was administered to diseased human lung tissue from….
Curia Supports Replicate Bioscience’s Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine
Supply of drug substance manufactured under cGMP supports first-in-human clinical study for RBI-4000 novel self-replicating RNA (srRNA)….
KBI Biopharma Expands Global Portfolio With Launch of SUREmAb for Faster Monoclonal Antibody Development & Manufacturing
KBI Biopharma, Inc., a JSR Life Sciences company, recently announced the launch of SUREmAb, an offering built on the robustness of KBI’s SUREtechnology Platform, that…
Salipro Biotech Enters Research Collaboration With Sumitomo Pharma to Advance Drug Discovery Program
Salipro Biotech AB recently announced that it has entered into a research collaboration with Sumitomo Pharma Co., Ltd. to reveal the mechanism of action and…
Spinogenix Awarded $3-Million NIH Grant to Support Continued Development of the First Synaptic Regenerative Therapeutic for Alzheimer’s Disease
Spinogenix, Inc. recently announced a second grant award by the National Institute of Health (NIH). The new $3- million grant titled Development of a Novel,…
Lisata Therapeutics Announces First Patient Treated in BOLSTER Trial Novel Tumor-Targeting & Penetrating Peptide in Patients With Advanced Solid Tumors
Lisata Therapeutics, Inc. recently announced treatment of the first patient in the head and neck squamous cell carcinoma cohort of the BOLSTER trial, by Dr.…
